COLLPLANT BIOTECH. IS-01 (F:CPT) — Market Cap & Net Worth
Market Cap & Net Worth: COLLPLANT BIOTECH. IS-01 (CPT)
COLLPLANT BIOTECH. IS-01 (F:CPT) has a market capitalization of $5.48 Million (€4.69 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #28498 globally and #2450 in its home market, demonstrating a 37.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COLLPLANT BIOTECH. IS-01's stock price €3.98 by its total outstanding shares 1890821 (1.89 Million). Also see COLLPLANT BIOTECH. IS-01 (CPT) total assets for a full breakdown of the balance sheet.
COLLPLANT BIOTECH. IS-01 Market Cap History: 2026 to 2026
COLLPLANT BIOTECH. IS-01's market capitalization history from 2026 to 2026. Data shows growth from $8.80 Million to $8.80 Million (0.00% CAGR). Also see how efficiently does COLLPLANT BIOTECH. IS-01 generate cash for how efficiently the company converts equity into cash flow.
COLLPLANT BIOTECH. IS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COLLPLANT BIOTECH. IS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check COLLPLANT BIOTECH. IS-01 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CPT by Market Capitalization
Companies near COLLPLANT BIOTECH. IS-01 in the global market cap rankings as of September 19, 2026. Review CPT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to COLLPLANT BIOTECH. IS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
COLLPLANT BIOTECH. IS-01 Historical Marketcap From 2026 to 2026
Between 2026 and today, COLLPLANT BIOTECH. IS-01's market cap moved from $8.80 Million to $ 8.80 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €8.80 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of COLLPLANT BIOTECH. IS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.48 Million USD |
| MoneyControl | $5.48 Million USD |
| MarketWatch | $5.48 Million USD |
| marketcap.company | $5.48 Million USD |
| Reuters | $5.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more